- Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea
-
Jung SI, Shin JH, Choi HJ, Ju MY, Kim SH, Lee WG, Park YJ, Lee K, Korean Study Group for Candidemia
- KMID: 2434484
- Ann Lab Med.
- 2012 Nov;32(6):426-428.
The in vitro antifungal susceptibility of 636 Candida bloodstream isolates collected from 15 tertiary hospitals in Korea was determined using the Vitek-2 yeast susceptibility system (bioMerieux, France). Overall susceptibility rates... -
- CITED
-
- Close
- SHARE
-
- Close
- In Vitro Fluconazole and Voriconazole Susceptibilities of Candida Bloodstream Isolates in Korea: Use of the CLSI and EUCAST Epidemiological Cutoff Values
-
Jang MJ, Shin JH, Lee WG, Kim MN, Lee K, Lee HS, Lee MK, Chang CL, Jang HC, Song ES, Kim SH, Shin MG, Suh SP, Ryang DW
- KMID: 1781321
- Ann Lab Med.
- 2013 May;33(3):167-173.
- doi: 10.3343/alm.2013.33.3.167
BACKGROUND: At present, the clinical breakpoints (CBPs) of both fluconazole and voriconazole are available only for 3 common Candida species in the Clinical and Laboratory Standards Institute (CLSI) and the... -
- CITED
-
- Close
- SHARE
-
- Close
- Accumulation of argpyrimidine, a methylglyoxal-derived advanced glycation end product, increases apoptosis of lens epithelial cells both in vitro and in vivo
-
Kim J, Kim OS, Kim CS, Sohn E, Jo K, Kim JS
- KMID: 1120135
- Exp Mol Med.
- 2012 Feb;44(2):167-175.
- doi: 10.3858/emm.2012.44.2.012
The formation of advanced glycation end products (AGEs) has been considered to be a potential causative factor of injury to lens epithelial cells (LECs). Damage of LECs is believed to... -
- CITED
-
- Close
- SHARE
-
- Close
- Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells
-
Park TH, Kwon HC, Kim HJ, Han JY, Jeong JS, Han H, Seo CY, Kwak JY, Park JI
- KMID: 1089462
- Exp Mol Med.
- 2005 Oct;37(5):507-511.
Imatinib mesylate is a selective Bcr/Abl kinase inhibitor and an effective anticancer agent for Bcr/Abl-positive chronic myelogenous leukemia. Most patients in chronic phase maintain durable responses; however, many in blast... -
- CITED
-
- Close
- SHARE
-
- Close
